Formulation of the microbicide inp0341 for in vivo protection against a vaginal challenge by chlamydia trachomatis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Pedersen, Christian ^a   Slepenkin, Anatoly ^b   Andersson, Sara B E ^a   Fagerberg, Jonas H ^a   Bergströ, Christel A S ^a   Peterson, Ellena M ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; INP 0341; MICROBICIDE; POLYACRYLIC ACID; POLYMER; UNCLASSIFIED DRUG; AGENTS USED INTRAVAGINALLY; ANTIINFECTIVE AGENT; DELAYED RELEASE FORMULATION; HYDRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHLAMYDIASIS; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; FEMALE; FLOW KINETICS; GEL; IN VITRO STUDY; INFECTION PREVENTION; LIMIT OF DETECTION; MOUSE; NONHUMAN; OSMOLALITY; PH MEASUREMENT; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; VAGINITIS; ANIMAL; CHEMISTRY; CHLAMYDIA TRACHOMATIS; DELAYED RELEASE FORMULATION; DISEASE MODEL; HELA CELL LINE; HUMAN; LYMPHOGRANULOMA VENEREUM; MICROBIOLOGY; PHARMACOLOGY; VAGINA;

ANIMALS; ANTI-INFECTIVE AGENTS; CHLAMYDIA TRACHOMATIS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HUMANS; HYDRAZINES; LYMPHOGRANULOMA VENEREUM; MICE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84908675954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110918     Document Type: Article

References (25)

1. Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H, et al. (2012) In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Ag 40: 354-360.
2. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M (2005) Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 73: 3104-3114.
3. Chu H, Slepenkin A, Elofsson M, Keyser P, de la Maza LM, et al. (2010) Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae. Int J Antimicrob Agents 36: 145-150.
4. Slepenkin A, Enquist PA, Hagglund U, de la Maza LM, Elofsson M, et al. (2007) Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun 75: 3478-3489.
5. Chu H, Slepenkin A, Elofsson M, Keyser P, Peterson EM (2010) Characterization of the inhibition of HSV-2 in vitro by INPs, a class of salicylidene acylhydrazide compounds; 2010; San Diego, California. 141.
6. Slepenkin A, Chu H, Elofsson M, Keyser P, Peterson EM (2011) Protection of Mice From a Chlamydia trachomatis Vaginal Infection Using a Salicylidene Acylhydrazide, a Potential Microbicide. J Infect Dis 204: 1313-1320.
7. Kieweg SL, Katz DF (2006) Squeezing Flows of Vaginal Gel Formulations Relevant to Microbicide Drug Delivery. J Biomech Eng 128: 540-553.
8. Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, et al. (2012) Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity. PLoS ONE 7: e48328.
9. Garg S, Tambwekar KR, Vermani K, Garg A, Kaul CL, et al. (2001) Compendium of Pharmaceutical Excipients for Vaginal Formulations. Pharm Technol Drug Deliv. 14-24.
10. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, et al. (2001) Tests of BufferGel for Contraception and Prevention of Sexually Transmitted Diseases in Animal Models. Sex Transm Dis 28: 417-423.
11. Peterson EM, You JZ, Motin V, de la Maza LM (1999) Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar. Vaccine 17: 2901-2907.
12. Khamesipour A, Pal S, Peterson EM, de la Maza LM (1994) Induction of infertility by the Chlamydia trachomatis mouse pneumonitis biovar in strains of mice that differ in their response to the 60 kDa heat shock protein. J Reprod Fertil 101: 287-294.
13. Peterson EM, Zhong GM, Carlson E, de la Maza LM (1988) Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun 56: 885-891.
14. Dahlgren MK, Zetterström CE, Gylfe Å, Linusson A, Elofsson M (2010) Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia. Bioorgan Med Chem 18: 2686-2703.
15. Bergström CS, Norinder U, Luthman K, Artursson P (2002) Experimental and Computational Screening Models for Prediction of Aqueous Drug Solubility. Pharm Res 19: 182-188.
16. Owen DH, Katz DF (1999) A vaginal fluid simulant. Contraception 59: 91-95.
17. Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, et al. (2011) Vaginal Microbicide Gel for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1. Antimicrob Agents Ch 55: 1650-1660.
18. Owen DH, Peters JJ, Katz DF (2000) Rheological properties of contraceptive gels. Contraception 62: 321-326.
19. Shukla NB, Daraboina N, Madras G (2009) Oxidative and photooxidative degradation of poly(acrylic acid). Polym Degrad Stabil 94: 1238-1244.
20. Balakrishnan A, Rege BD, Amidon GL, Polli JE (2004) Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci 93: 2064-2075.
21. Holmberg K, Jönsson B, Kronberg B, Lindman B (2003) Surfactants and polymers in aqueous solution. Chichester: John Wiley & Sons Ltd.
22. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
23. nd Annual Meeting San Francisco, Abstract 1816.
24. Andrews GP, Laverty TP, Jones DS (2009) Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 71: 505-518.
25. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and effectiveness of BufferGel and 0.5% PRO 2000 gel for the prevention of HIV infection in women. AIDS 25: 957-966.